| Title |
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, August 2010
|
| DOI | 10.1007/s10549-010-1090-x |
| Pubmed ID | |
| Authors |
Teemu T. Junttila, Guangmin Li, Kathryn Parsons, Gail Lewis Phillips, Mark X. Sliwkowski |
| Abstract |
Trastuzumab (Herceptin(®)) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2. Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clinical benefits of trastuzumab with a potent microtubule-disrupting drug, DM1 (a maytansine derivative). Currently T-DM1 is being tested in multiple clinical trials. The mechanisms of action for trastuzumab include inhibition of PI3K/AKT signaling pathway, inhibition of HER-2 shedding and Fcγ receptor mediated engagement of immune cells, which may result in antibody-dependent cellular cytotoxicity (ADCC). Here we report that T-DM1 retains the mechanisms of action of unconjugated trastuzumab and is active against lapatinib resistant cell lines and tumors. |
Mendeley readers
The data shown below were compiled from readership statistics for 340 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| Italy | 1 | <1% |
| Turkey | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 334 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 66 | 19% |
| Student > Ph. D. Student | 62 | 18% |
| Student > Bachelor | 39 | 11% |
| Student > Master | 38 | 11% |
| Other | 23 | 7% |
| Other | 37 | 11% |
| Unknown | 75 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 66 | 19% |
| Biochemistry, Genetics and Molecular Biology | 61 | 18% |
| Medicine and Dentistry | 40 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 29 | 9% |
| Chemistry | 25 | 7% |
| Other | 31 | 9% |
| Unknown | 88 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2023.
All research outputs
#1,470,572
of 26,017,215 outputs
Outputs from Breast Cancer Research and Treatment
#172
of 5,117 outputs
Outputs of similar age
#4,694
of 108,804 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#3
of 50 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,117 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,804 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.